First-of-its-kind study shows sustained Zepbound use in older adults with obesity lowers costs, reinforcing the potential value of the Medicare GLP-1 Bridge program Individuals treated with Zepbound had lower rates of hospital admissions and emergency department visits INDIANAPOLIS, Aug.
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S.
Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis. Q2 2026 reported and non-GAAP EPS included $3.03 of acquired IPR&D charges compared to
INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration ( FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health INDIANAPOLIS and NEW YORK, July 16, 2026 /PRNewswire/ -- Eli Lilly and
In the news release, Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment, issued July 9, 2026 by Eli Lilly and Company over PR Newswire, we are advised by the company that changes have been
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical Oncology BRUIN CLL-313 is the first Phase 3 study to evaluate a
New multi-country campaign launches in Geneva alongside the European Academy of Neurology Congress GENEVA, SWITZERLAND, June 26, 2026 -- Today, Eli Lilly and Company (NYSE: LLY) launches The Memory Radio Station, a travelling public radio station and exhibition dedicated to the memories that makes
A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients beginning July 1 INDIANAPOLIS, June 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
INDIANAPOLIS, June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for the treatment of
INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on September 10, 2026, to shareholders of record at the close of
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients previously treated with a covalent BTK inhibitor, reflects current practice patterns These data will be highlighted in a late-breaking oral
INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients with
In the national campaign Watch This, O'Neal gets real about living with moderate obstructive sleep apnea (OSA) and the moment he decided to do something about it Zepbound ® (tirzepatide) is the first and only prescription medicine for moderate-to-severe OSA in adults with obesity and should be used
EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the start INDIANAPOLIS, June 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a regimen
In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mg In ACHIEVE-2 and ACHIEVE-5, Foundayo delivered significant improvements in blood sugar and weight, with up to 68.6% and 69.1% of participants
In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%) In ATTAIN-2, women taking Foundayo lost significant weight across all stages of menopause, despite the additional challenge of living with type 2
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and
Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL will be highlighted in a late-breaking oral presentation Ajax Therapeutics, which Lilly has agreed
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease These data will be